Avalere’s Post

RARE DISEASE CASE STUDY: A #lifesciences organization was interested in characterizing and quantifying the total burden of a #raredisease for patients, caregivers, and US society at large. They asked #AvalereExperts to research the full range of medical and nonmedical costs associated with the disease. Read the full case study: https://lnkd.in/eUxdCqG6 ���� Interested in diving deeper on #rarediseases? Download our free eBook on the policy, market access, and evidence landscape of rare disease in the United States and globally: https://lnkd.in/eeE_zyvk #healthpolicy #marketaccess #evidencegeneration #healthcare #rarediseases

How will the #healthinsurance market shift over the next six years, and what can plans do now to prepare? In a new series, #AvalereExperts are exploring what #healthplans need to know as they navigate the next few years. Read our latest Insights on: 🔎 Approaches to provider contracting and utilization management: https://lnkd.in/ecYKtZCH 🔎 Shifts in clinical care delivery: https://lnkd.in/eUKhj44e

🌟 We're Expanding Our Team! 🌟 Do you have a passion for #healthcare and a desire to drive positive change? We’re looking for talented professionals to join our #healthpolicy experts in solving some of the industry's toughest challenges. Check out our current openings: https://lnkd.in/e_z3UFW #healthpolicyjobs

Budgeting season offers #HEOR teams the opportunity to revisit research and evidence needs and update their commercialization strategy based on market dynamics. In a new Insight, #AvalereExperts Taylor Schwartz, Laura T. Housman, MPH, MBA, DrPH(c), Nancy El Hoyek, Josephine Lloyd, and Nicole Betor detail five elements of a robust HEOR strategy: https://lnkd.in/epsnvH9q

By prioritizing personalized care and comprehensive support, we can enhance patient outcomes and ensure that women have access to the resources they need throughout their healthcare journey. Read the latest research and analysis on #womenshealth from Jessica Cortez, CPB and other #AvalereExperts: https://lnkd.in/eFrc2RBN #patients #womenshealth #healthcare

With complex rules and logic, risk adjustment submissions are challenging. Make sure your risk adjustable claims make their way all the way from intake to submission regardless of the source of your claims, be they generated in-house or by a vendor. We recently helped a plan recoup $20M in missed risk adjustment reimbursement through a stringent review of their data. Contact us to find out how we can help analyze your data at every step of the process to improve the accuracy and completeness of your risk adjustment submissions: https://lnkd.in/ejepc_X6 #riskadjustment #healthplans

💡 NEW ANALYSIS 💡 #AvalereExperts Kylie Stengel, Kelly Brantley, Nadia Mercado, and Shruthi Donthi examined historic trends to assess whether the recent decrease in LIS benchmark plan options under the #IRA correlates with more LIS enrollees paying premiums for their #PartD coverage. They found that that from 2023 to 2024, the number of LIS enrollees paying a Part D premium increased by more than 1 million. Read their detailed findings: https://lnkd.in/eCcnKaq8 #InflationReductionAct #Medicare #MedicarePartD

While the FDA’s final rule on #LDTs was released in April, the impact is still being felt across the industry. #AvalereExpert Laura T. Housman, MPH, MBA, DrPH(c) shares her perspective on how stakeholders should take advantage of this new landscape. Read her article in MedTech Intelligence: https://lnkd.in/e5Ke2UFD #labdevelopedtests #diagnostics #healthpolicy

In overturning Chevron deference, the Supreme Court opened several questions on the future of #healthpolicy, with wide-ranging implications for life sciences firms, health plans, provider groups, patient organizations, and other #healthcare stakeholders. Tap into Avalere’s deep bench of #healthpolicy experts with extensive experience in federal agencies and rulemaking to navigate what the rule means for you. Connect with us here: https://lnkd.in/eV3uymgQ #lifesciences #lifesciencesindustry #healthplans #patients #providers #ChevronDeference

The 2025 plan year has been extraordinarily tumultuous, and there are multiple reasons a health plan’s estimate of the #NAMBA may be less precise than in other years. In a new Insight, #AvalereExperts Emily Gillen, PhD, Kirsten Stryker Blasch, Nadia Mercado, and Sean Creighton explain how the drivers of this uncertainty--combined with increased plan liability under the #IRA--necessitate plans to strategize for their Rebate Reallocation process. Read their analysis: https://lnkd.in/etd5wthU